

**Supplementary Table 2. Baseline characteristics of subjects according to coronavirus disease 2019 infection before matching (n = 62,909)**

Characteristic	Control (n = 61,265)	Case (n = 1,644)	p value
Male sex	32,265 (52.7)	714 (43.4)	< 0.0001
Age, yr	67.8 ± 14.8	65.5 ± 13.7	< 0.0001
Age over 65 yr	37,502 (61.2)	850 (51.7)	< 0.0001
Region of diagnosis			
Daegu & Gyeongbuk	8,962 (14.6)	1,098 (66.8)	< 0.0001
Tested hospital			
3rd	21,810 (35.6)	323 (19.7)	< 0.0001
Comorbidities			
Diabetes	22,206 (36.3)	512 (31.1)	< 0.0001
Dyslipidemia	37,885 (61.8)	917 (55.8)	< 0.0001
MI & Stroke	23,609 (38.5)	456 (27.7)	< 0.0001
Heart failure	19,197 (31.3)	339 (20.6)	< 0.0001
Liver disease	39,165 (63.9)	962 (58.5)	< 0.0001
Cancer	14,299 (23.3)	172 (10.5)	< 0.0001
COPD	23,504 (38.4)	459 (27.9)	< 0.0001
Asthma	24,261 (39.6)	466 (28.4)	< 0.0001
ESRD with dialysis	3,840 (6.3)	18 (1.1)	< 0.0001
Immunocompromised status	7,696 (12.6)	185 (11.3)	0.1137
Charlson comorbidity index			
0	3,312 (5.4)	196 (11.9)	< 0.0001
1	6,417 (10.5)	278 (16.9)	
≥ 2	51,536 (84.1)	1,170 (71.2)	
Exposure to RAAS inhibitors			
RAAS inhibitors	45,168 (73.7)	1,217 (74.0)	0.7842
ACE inhibitors	3,589 (5.9)	85 (5.2)	0.2405
ARBs	43,240 (70.6)	1,172 (71.3)	0.5324
Death	2,583 (4.2)	165 (10.0)	< 0.0001

Values are presented as number (%) or mean ± SD.

MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; RAAS, renin-angiotensin-aldosterone system; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.